BeOne Medicines sees strong sales growth amid upcoming Phase 3 results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 06 2026
0mins
Should l Buy ONC?
BeOne Medicines AG's stock fell by 5.01% as it crossed below the 5-day SMA, reflecting a downturn despite positive market conditions with the Nasdaq-100 up 1.35% and S&P 500 up 0.82%.
The decline in BeOne Medicines' stock comes amid strong sales of its blood cancer therapy, Brukinsa, and expectations to announce Phase 3 study results for MCL in the first half of 2026. This positive outlook contrasts with the stock's performance, indicating a potential sector rotation as investors reassess their positions in the biopharmaceutical sector.
The upcoming Phase 3 results and regulatory approval opportunities for sonrotoclax and BGB-16673 could significantly impact BeOne's future growth trajectory, making it a company to watch in the evolving healthcare landscape.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ONC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ONC
Wall Street analysts forecast ONC stock price to rise
11 Analyst Rating
11 Buy
0 Hold
0 Sell
Strong Buy
Current: 323.870
Low
385.00
Averages
403.76
High
424.00
Current: 323.870
Low
385.00
Averages
403.76
High
424.00
About ONC
BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BeiGene to Announce Q1 Earnings on April 15
- Earnings Announcement Schedule: BeiGene is set to release its Q1 2023 earnings report on April 15 after market close, with consensus estimates predicting an EPS of $0.85 and revenue of $1.45 billion, indicating a stable performance in the market.
- Performance Exceeding Expectations: Over the past year, BeiGene has beaten EPS estimates 100% of the time and revenue estimates 75% of the time, showcasing the company's strong capabilities in profitability and market expectation management.
- Expectation Revision Dynamics: In the last three months, EPS estimates have seen two upward revisions and one downward revision, while revenue estimates have experienced two upward and two downward revisions, reflecting a cautiously optimistic market outlook on the company's future performance.
- Market Environment Impact: Amid disruptions in the Middle East, over $10 billion worth of healthcare stocks on Wall Street are considered oversold, and as a participant in the industry, BeiGene may be affected by fluctuations in market sentiment.
See More
BeOne Medicines Receives Conditional Approval for Lung Cancer Treatment in China
- Drug Approval: BeOne Medicines announced that its bispecific T-cell engager tarlatamab, developed in partnership with Amgen, received conditional approval in China as a second-line treatment for extensive-stage small cell lung cancer, marking a significant milestone for the company in the Chinese market.
- Market Potential: Approximately 160,000 patients are diagnosed with small cell lung cancer in China each year, accounting for nearly 15% of global lung cancer cases, providing a substantial market opportunity for tarlatamab, especially given the limited efficacy of existing treatments.
- Treatment Need: Despite platinum-based chemotherapy being the main first-line therapy, the majority of small cell lung cancer patients experience disease progression within six months, thus the approval of tarlatamab offers a new treatment option that could potentially improve survival rates and quality of life for these patients.
- Collaboration Background: BeOne Medicines has been developing tarlatamab in Mainland China under a licensing agreement with Amgen since 2019, and this approval not only strengthens the partnership between the two companies but also lays a foundation for BeOne's further development in the biopharmaceutical sector.
See More
BEONE MEDICINES: TRUIST SECURITIES LOWERS TARGET PRICE TO $411, DOWN FROM $412
- Price Adjustment: Truis has cut the target price for Beonemedicine from $412 to $411.
- Market Impact: This adjustment reflects changes in market conditions and expectations for Beonemedicine's performance.
See More
BeOne Medicine's BGB-B2033 Receives FDA Orphan Drug Designation
- Orphan Drug Status: BeOne Medicine's BGB-B2033 has received orphan drug designation from the FDA for hepatocellular carcinoma, the most common type of liver cancer, marking a significant advancement in the company's oncology portfolio.
- Anti-Tumor Activity: BGB-B2033 is an IgG-based bispecific antibody currently in phase 1 trials targeting GPC3 and 4-1BB, demonstrating potential anti-tumor activity that could provide new treatment options for liver cancer patients.
- Combination Therapy Potential: BeOne indicates that the anti-tumor activity of BGB-B2033 may be enhanced when used in conjunction with Tevimbra (tislelizumab), an IgG4 anti-PD-1 monoclonal antibody, which could improve treatment outcomes.
- Market Outlook: With the orphan drug designation, BeOne Medicine's competitiveness in the liver cancer treatment market is strengthened, likely attracting increased investor interest in its future clinical developments and market potential.
See More
BeOne Medicines AG Raises 2026 Revenue Guidance Amid Strong Q4 Results
- Significant Revenue Growth: BeOne Medicines AG reported global revenues of $1.5 billion for Q4 2025, reflecting a 33% increase from the previous quarter, while projecting $5.3 billion for 2026, a 40% year-over-year growth, indicating strong market performance and growth potential.
- Strong Brukinsa Performance: The company's lymphoma and leukemia treatment, Brukinsa, generated revenues of $1.1 billion and $3.9 billion for Q4 and the full year, respectively, marking increases of 38% and 49% from prior periods, further solidifying its market position in oncology.
- Analyst Price Target Increase: On February 27, Truist Securities raised its price target for BeOne Medicines AG from $400 to $412 while maintaining a Buy rating, reflecting confidence in the company's future growth, especially following the release of its fiscal 2026 revenue guidance.
- Market Expectation Pressure: Although the fiscal 2026 revenue guidance ranges from $6.2 billion to $6.4 billion, closely aligning with consensus estimates of $6.4 billion, analysts noted that this expectation has added pressure on the stock price, indicating a cautious market outlook on the company's future growth.
See More
BeiGene to Announce Q4 Earnings on February 26
- Earnings Announcement: BeiGene is set to release its Q4 2023 earnings report on February 26 before the market opens, with investors keenly awaiting performance insights to gauge future growth potential.
- Earnings Expectations: The consensus EPS estimate stands at $1.30, with revenue projected at $1.45 billion, reflecting a robust year-over-year growth of 31.8%, indicating strong momentum in the biopharmaceutical sector.
- Estimate Revisions: Over the past three months, EPS estimates have seen no upward revisions but five downward adjustments, while revenue estimates experienced one upward revision and two downward adjustments, suggesting a cautious market outlook on the company's performance.
- Industry Context: The earnings release will coincide with BeOne Medicines AG's presentation at the 44th Annual J.P. Morgan Healthcare Conference, potentially influencing investor sentiment towards the broader biopharmaceutical industry.
See More
BeiGene to Announce Q1 Earnings on April 15
- Earnings Announcement Schedule: BeiGene is set to release its Q1 2023 earnings report on April 15 after market close, with consensus estimates predicting an EPS of $0.85 and revenue of $1.45 billion, indicating a stable performance in the market.
- Performance Exceeding Expectations: Over the past year, BeiGene has beaten EPS estimates 100% of the time and revenue estimates 75% of the time, showcasing the company's strong capabilities in profitability and market expectation management.
- Expectation Revision Dynamics: In the last three months, EPS estimates have seen two upward revisions and one downward revision, while revenue estimates have experienced two upward and two downward revisions, reflecting a cautiously optimistic market outlook on the company's future performance.
- Market Environment Impact: Amid disruptions in the Middle East, over $10 billion worth of healthcare stocks on Wall Street are considered oversold, and as a participant in the industry, BeiGene may be affected by fluctuations in market sentiment.
See More
BeOne Medicines Receives Conditional Approval for Lung Cancer Treatment in China
- Drug Approval: BeOne Medicines announced that its bispecific T-cell engager tarlatamab, developed in partnership with Amgen, received conditional approval in China as a second-line treatment for extensive-stage small cell lung cancer, marking a significant milestone for the company in the Chinese market.
- Market Potential: Approximately 160,000 patients are diagnosed with small cell lung cancer in China each year, accounting for nearly 15% of global lung cancer cases, providing a substantial market opportunity for tarlatamab, especially given the limited efficacy of existing treatments.
- Treatment Need: Despite platinum-based chemotherapy being the main first-line therapy, the majority of small cell lung cancer patients experience disease progression within six months, thus the approval of tarlatamab offers a new treatment option that could potentially improve survival rates and quality of life for these patients.
- Collaboration Background: BeOne Medicines has been developing tarlatamab in Mainland China under a licensing agreement with Amgen since 2019, and this approval not only strengthens the partnership between the two companies but also lays a foundation for BeOne's further development in the biopharmaceutical sector.
See More
BEONE MEDICINES: TRUIST SECURITIES LOWERS TARGET PRICE TO $411, DOWN FROM $412
- Price Adjustment: Truis has cut the target price for Beonemedicine from $412 to $411.
- Market Impact: This adjustment reflects changes in market conditions and expectations for Beonemedicine's performance.
See More
BeOne Medicine's BGB-B2033 Receives FDA Orphan Drug Designation
- Orphan Drug Status: BeOne Medicine's BGB-B2033 has received orphan drug designation from the FDA for hepatocellular carcinoma, the most common type of liver cancer, marking a significant advancement in the company's oncology portfolio.
- Anti-Tumor Activity: BGB-B2033 is an IgG-based bispecific antibody currently in phase 1 trials targeting GPC3 and 4-1BB, demonstrating potential anti-tumor activity that could provide new treatment options for liver cancer patients.
- Combination Therapy Potential: BeOne indicates that the anti-tumor activity of BGB-B2033 may be enhanced when used in conjunction with Tevimbra (tislelizumab), an IgG4 anti-PD-1 monoclonal antibody, which could improve treatment outcomes.
- Market Outlook: With the orphan drug designation, BeOne Medicine's competitiveness in the liver cancer treatment market is strengthened, likely attracting increased investor interest in its future clinical developments and market potential.
See More
BeOne Medicines AG Raises 2026 Revenue Guidance Amid Strong Q4 Results
- Significant Revenue Growth: BeOne Medicines AG reported global revenues of $1.5 billion for Q4 2025, reflecting a 33% increase from the previous quarter, while projecting $5.3 billion for 2026, a 40% year-over-year growth, indicating strong market performance and growth potential.
- Strong Brukinsa Performance: The company's lymphoma and leukemia treatment, Brukinsa, generated revenues of $1.1 billion and $3.9 billion for Q4 and the full year, respectively, marking increases of 38% and 49% from prior periods, further solidifying its market position in oncology.
- Analyst Price Target Increase: On February 27, Truist Securities raised its price target for BeOne Medicines AG from $400 to $412 while maintaining a Buy rating, reflecting confidence in the company's future growth, especially following the release of its fiscal 2026 revenue guidance.
- Market Expectation Pressure: Although the fiscal 2026 revenue guidance ranges from $6.2 billion to $6.4 billion, closely aligning with consensus estimates of $6.4 billion, analysts noted that this expectation has added pressure on the stock price, indicating a cautious market outlook on the company's future growth.
See More
BeiGene to Announce Q4 Earnings on February 26
- Earnings Announcement: BeiGene is set to release its Q4 2023 earnings report on February 26 before the market opens, with investors keenly awaiting performance insights to gauge future growth potential.
- Earnings Expectations: The consensus EPS estimate stands at $1.30, with revenue projected at $1.45 billion, reflecting a robust year-over-year growth of 31.8%, indicating strong momentum in the biopharmaceutical sector.
- Estimate Revisions: Over the past three months, EPS estimates have seen no upward revisions but five downward adjustments, while revenue estimates experienced one upward revision and two downward adjustments, suggesting a cautious market outlook on the company's performance.
- Industry Context: The earnings release will coincide with BeOne Medicines AG's presentation at the 44th Annual J.P. Morgan Healthcare Conference, potentially influencing investor sentiment towards the broader biopharmaceutical industry.
See More
